← Back
Data updated: Jun 28, 2026
GLENMARK GENERICS
Generics Pharmaceuticals
GLENMARK GENERICS is a generic drug manufacturer with 4 FDA-approved products.
1989
Since
4
Drugs
-
Trials
0
New Drugs (2yr)
GLENMARK GENERICS's Key Drugs
GLENMARK GENERICS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
No active drugs
GLENMARK GENERICS's Recent FDA Approvals
New NDA/BLA approvals for GLENMARK GENERICS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
GLENMARK GENERICS's Therapeutic Areas
Disease areas where GLENMARK GENERICS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
GLENMARK GENERICS Pipeline Snapshot
Active clinical trials for GLENMARK GENERICS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1989-01-03
- Latest
- 1999-05-11
- Applications
- 7